Navigation Links
OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
Date:7/29/2008

hat statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the issuance of a patent covering a pharmaceutical composition of zonisamide in combination with a series of marketed atypical antipsychotics, the efficacy and safety of OREX- 003, and the timing of the initiation of the Company's OZ-101 clinical trial. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Company's business, including, without limitation: the progress and timing of the Company's clinical trials or the development of OREX-003; the potential for adverse safety findings relating to its product candidates to delay or prevent regulatory filings; and Orexigen or its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward- looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
2. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
3. United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
4. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
5. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
6. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
7. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
8. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
9. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
10. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
11. Organizational Changes at Silence Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... disease risks, the biological characteristics people care most about ... heightthe textbook example of a complex traitattributes like risk ... genetic and environmental influences, making it challenging to find ... typically mate two individuals that differ in key waysfor ... study their descendents, looking for genes that tend to ...
(Date:9/19/2014)... YORK , Sept. 19, 2014  An entire ... forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) – ... and legs, causing extreme muscle atrophy, weakness, and foot ... the US and millions worldwide. CMT is a progressive ... of their legs, requiring mobility devices such as leg ...
(Date:9/19/2014)... Florida , September 19, 2014 ... release latest developments, patents and results of studies and ... Eli Lilly and Company (NYSE: LLY ), ... Corporation (NASDAQ: CELG ) and Arena Pharmaceuticals ... a leader in developing prodrug therapeutics for the treatment ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... , CINCINNATI , June 3 Kendle ... organization (CRO), today announced it is ranked a top CRO ... Survey. Kendle is the only CRO to be ranked consistently ... four years in the annual U.S. and European site surveys ...
... June 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... Wolff , executive vice president and CFO, will provide an update on the ... business strategy at two investor conferences during the month of June: , ... The Jefferies 2010 ...
... June 3 The John Theurer Cancer Center ... that will be presented at the American Society of Clinical ... – 8, 2010 in Chicago . Research highlights include ... lymphoma, the efficacy and safety of a new genetically engineered ...
Cached Biology Technology:Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 2Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 3Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences 2New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 2New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 3New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 4New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 5New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 6
(Date:9/21/2014)... Carbon dioxide emissions, the main contributor to global warming, are ... high of 40 billion tonnes. , The 2.5 per cent ... Global Carbon Project, which is co-led in the UK by ... the University of East Anglia and the College of Engineering, ... It comes ahead of the New York Climate Summit, where ...
(Date:9/21/2014)... recent years, new strains of bacteria have emerged that ... superbugs, including drug-resistant forms of tuberculosis and staphylococcus, infect ... least 23,000. Despite the urgent need for new treatments, ... in the past decade. , MIT engineers have now ... a gene-editing system that can disable any target gene, ...
(Date:9/21/2014)... MA -- Shellfish such as mussels and barnacles secrete ... or ship hulls, even underwater. Inspired by these natural ... materials that could be used to repair ships or ... their new waterproof adhesives, the MIT researchers engineered bacteria ... mussel proteins as well as a bacterial protein found ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Battling superbugs 2Battling superbugs 3Battling superbugs 4Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3
... (IUPAB) and Springer will launch the journal Biophysical ... is the new official journal of the IUPAB, ... societies with approximately 15,000 members. The entire IUPAB ... journal in order to demonstrate the close affiliation between ...
... football players who gain weight to add power to their ... diabetes and heart disease later in life, a new study ... and defensive linemen who underwent a battery of tests for ... at least three of five risk factors that indicate a ...
... flies snore, but rest assured that when you,re asleep ... January 2009 issue of the journal GENETICS ... City have shown that the circadian rhythms (sleep/wake cycles) ... of the same "cellular machinery" as that of humans. ...
Cached Biology News:Biophysical Reviews makes debut in 2009 2Athletes not spared from health risks of metabolic syndrome 2Athletes not spared from health risks of metabolic syndrome 3When it comes to sleep research, fruit flies and people make unlikely bedfellows 2
...
... robotic workstations is designed for laboratories with ... ideal automation platform for routine sample preparation ... improving throughput, process consistency and safety. ... allows you to control the robotic and ...
...
...
Biology Products: